Amylin (1-37), human acetate (hIAPP (1-37), acetate), a peptide hormone containing 37 amino acids secreted by the pancreas in conjunction with insulin, inhibits glucagon secretion and produces satiety during glucose homeostasis, and is a major component of amyloid deposits in the pancreas of patients with type 2 diabetes.

Selected pharmaco-chaperones were co-administered intraperitoneally with Amylin (1-37), human acetate into hIAPP transgenic mice for 5 consecutive days. Compared to hIAPP-only controls, mice receiving chaperones B and E showed markedly reduced islet amyloid deposition, preserved islet architecture, and enhanced insulin immunoreactivity[1].